Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Ravulizumab
(Ultomiris, ULTOMIRIS)		[1] Ravulizumab[1] Ravulizumab (Ultomiris, ULTOMIRIS) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[7] 2, 11, 13, 50, 62, 66, 109 💬
2Ravulizumab obds
(Ultomiris, ULTOMIRIS)		[1] Ravulizumab[1] Ravulizumab (Ultomiris, ULTOMIRIS) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬
3Ultomiris[1] Ravulizumab[1] Ravulizumab (Ultomiris, ULTOMIRIS) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[7] 2, 11, 13, 50, 62, 66, 109 💬
4Ultomiris - 300 MG - concentrato PER soluzione PER infusione - USO endovenoso - flaconcino (vetro) 3 ML (100 MG / ML) - 1 flaconcino[1] Ravulizumab[1] Ravulizumab (Ultomiris, ULTOMIRIS) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬
5Ultomiris 1,100 MG/11 ML[1] Ravulizumab[1] Ravulizumab (Ultomiris, ULTOMIRIS) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 11 💬
6Ultomiris 300 MG/30 ML[1] Ravulizumab[1] Ravulizumab (Ultomiris, ULTOMIRIS) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 66 💬
7Ultomiris 300MG/30ML[1] Ravulizumab[1] Ravulizumab (Ultomiris, ULTOMIRIS) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬